Richmond Pharmacology Opens New London Bridge Site
Posted:
3
March 2017
This decision marks the next step in Richmond Pharmacology’s continued growth, having already conducted over 300 studies in London since 2001, often in rare disease areas such as amyloidosis.
Richmond Pharmacology Opens New London Bridge Site
Dr Jorg Taubel, CEO of Richmond Pharmacology commented saying:“The opening of our new research facility is a sign of our continued commitment to working alongside the leading research hospitals and universities in the UK to deliver cutting-edge clinical research across vital disease areas.“Richmond are committed to making a significant and meaningful contribution to the health of the UK’s population and ensuring a sustainable future for the NHS through supporting the development of life changing and innovative medicines”
Medicines Marketing UK / EU vs US: Why Your Launch Strategy Needs a Continental Divide - Dr Lisa Campbell, Director of Regulatory Strategy
September 12, 2025
A UK CRO’s perspective on planning clinical trials for global success For pharmaceutical companies preparing for global expansion, launching in both the US and EU / UK markets often seems like the natural next step. Yet success in one region does not guarantee success in the other.
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
